Early efficacy of alendronate in treatment of osteoporotic vertebral compression fractures vertebroplasty postoperative residual pain
- VernacularTitle:阿仑膦酸钠治疗骨质疏松性脊柱压缩性骨折椎体成形术后残余疼痛的早期疗效观察
- Author:
He FANG
;
Fangming HE
;
Yinghua FU
- Publication Type:Journal Article
- Keywords:
alendronate;
osteoporotic vertebral compression fractures;
vertebroplasty
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;35(10):35-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy of alendronate in treatment of postoperative residual pain with osteoporotic vertebral compression fractures(OVCF) of vertebroplasty.Methods 62 patients with OVCF from September 2013 to October 2014 were divided into observation group and control group, each had 31 cases.All patients were given calcium carbonate D3 tablets 1 day after surgery, observation group were given alendronate on this basis.The degree of pain score between two groups pre-and post-treatment two weeks, one month, two months were observed and compared.Pain improvement in two groups were observed, and activity ability score, painkiller use and bone mineral density between two groups pre-and post-treatment were compared.Results The pain scores in observation group a month postoperative was (0.8 ±0.4) points and (0.4 ±0.2) points after two months, were significantly lower than those in control group[(1.6 ±0.7) points, (1.1 ±0.8) points, P<0.05].The excellent rate of pain improvement in observation group(83.87%) was significantly higher than that in control group (58.06%, P <0.05) .After treatment, activity ability score in observation group was (1.13 ±0.53) points and painkiller usage was (0.44 ±0.07) times per day, all significantly lower than those in control group [(1.79 ±0.89) points, (0.89 ±0.12) times per day, P<0.05].BMD level in observation group was (5.78 ±1.02)%, higher than that in control group[(3.21 ±0.79)%, P<0.05].Conclusion Alendronate in treatment of osteoporotic vertebral compression fractures vertebroplasty postoperative residual pain has good early outcome and low adverse reactions, and security is relatively high.
